Theralase® Technologies Inc.
Are you a media representative looking for content on Theralase®?
See below for access to: news releases, quotes from the management team and social media channel feeds.
Toronto, Ontario –November 23, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...0
Toronto, Ontario – November 13, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinica...0
Theralase Signs Agreement with University of Manitoba to Commence Development of Coronavirus Vaccine and Therapy
Toronto, Ontario – August 19, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...0
Toronto, Ontario – August 12, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...0
Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study (“Study II”) Progress
Results of the First 12 patients enrolled in the Phase II NMIBC Clinical Study Demonstrate a 58.3% Response 90 Days Post Initial Treatment Toronto,...0
In the News
Quotes from the Management Team
Shawn Shirazi, Ph.D., Chief Executive Officer, Theralase®
"Theralase is pleased that we have enrolled and successfully treated 12 patients in Study II and look forward to analyzing and reporting out on the clinical data, when clinically relevant. The Company’s immediate goal is to successfully enroll and treat 20 to 25 patients, who have received two treatment procedures, to provide clinical evidence to Health Canada and the FDA on the primary, secondary and tertiary clinical outcome objectives; which may then be used to support Breakthrough Therapy Designation (“BTD”) approval from the FDA.”
Dr. Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase®
“NMIBC is a recurrent and progressive cancer, which Theralase believes it’s TLD-1433 therapy can make a significant difference in. Current standards of care for NMIBC including BCG, chemotherapy and immunotherapy, are not curative in nature and unfortunately are associated with considerable morbidity. This underscores the urgent need for new treatment options like Theralase’s TLD-1433 PDT for patients contending with this debilitating and fatal disease.”
Dr. Michael Jewett, MD, FRCSC, FACS, Professor of Surgery (Urology) at the University of Toronto and the Chairman of Theralase’s Medical and Scientific Advisory Board
“I am pleased that the clinical results of the Study met its objectives demonstrating that the Theralase PDT technology has demonstrated potential as a treatment for bladder cancer.”
Dr. Girish Kulkarni, MD, PhD, FRCSC, an Associate Professor at the University of Toronto, Department of Surgery and Theralase’s Principal Investigator at University Health Network, Princess Margaret Cancer Centre
“I believe that TLD-1433 holds real potential as a treatment for NMIBC and I look forward to treating additional patients in the pivotal Phase II NMIBC clinical study”
Dr. Ashish Kamat, MD, MBBS, Professor of Urologic Oncology and Wayne B. Duddlesten Professor of Cancer Research, University of Texas, MD Anderson Cancer Center, member of Theralase’s Medical and Scientific Advisory Board
“Currently, cystectomy remains the safest treatment option available to patients, but if the Theralase PDT achieves its efficacy endpoint in a Phase II clinical study, then this will present patients with an attractive additional treatment option. The clinical data presented by Dr. Kulkarni suggests that the Theralase PDT treatment option may be just what the doctor ordered.”